Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5209079
Max Phase: Preclinical
Molecular Formula: C20H21F2N3O
Molecular Weight: 357.40
Associated Items:
ID: ALA5209079
Max Phase: Preclinical
Molecular Formula: C20H21F2N3O
Molecular Weight: 357.40
Associated Items:
Canonical SMILES: Fc1ccc(CO[C@H]2CCCN(Cc3ncn4ccccc34)C2)cc1F
Standard InChI: InChI=1S/C20H21F2N3O/c21-17-7-6-15(10-18(17)22)13-26-16-4-3-8-24(11-16)12-19-20-5-1-2-9-25(20)14-23-19/h1-2,5-7,9-10,14,16H,3-4,8,11-13H2/t16-/m0/s1
Standard InChI Key: HSKYGLYKZWIIPN-INIZCTEOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 357.40 | Molecular Weight (Monoisotopic): 357.1653 | AlogP: 3.79 | #Rotatable Bonds: 5 |
Polar Surface Area: 29.77 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.38 | CX LogP: 2.86 | CX LogD: 2.58 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.70 | Np Likeness Score: -1.64 |
1. Tolentino KT, Mashinson V, Vadukoot AK, Hopkins CR.. (2022) Discovery and characterization of benzyloxy piperidine based dopamine 4 receptor antagonists., 61 [PMID:35151866] [10.1016/j.bmcl.2022.128615] |
Source(1):